Zhang Yutian, Wang Tianlin, Han Junquan, Song Jielin, Yang Chaoshuai, Liang Lei, Li Huizhen, Wang Hong
Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Department of Gastroenterology, Tianjin University of Traditional Chinese Medicine Second Affiliated Hospital, Tianjin, China.
Front Pharmacol. 2025 Jun 9;16:1610498. doi: 10.3389/fphar.2025.1610498. eCollection 2025.
Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disease with overnutrition and insulin resistance (IR) as the main etiologic factors. Hepatic lipid accumulation is a central factor contributing to this cascade of changes. Consequently, therapeutic interventions that target hepatic lipid metabolism and inflammatory response pathways hold considerable promise for the treatment of NAFLD. Furthermore, there is a close link between the gut microbiota (GM) and host health. GM and its metabolites can rely on multiple complex pathways to be deeply involved in the occurrence and development of NAFLD, which is associated with a variety of mechanisms. This makes it difficult to achieve satisfactory therapeutic efficacy of drugs targeting a single specific mechanism. In this context, natural products have the advantage of intervening in multiple targets and high safety. Consequently, an increasing number of researchers are considering natural products as a potential breakthrough point for the treatment of NAFLD. Notably, natural products influence intestinal mucosal permeability and metabolite production by regulating the abundance of beneficial flora in GM, which in turn regulates lipid metabolism to reduce hepatic steatosis and inhibit the progression of NAFLD. This paper reviews the research progress of natural products intervening in NAFLD through GM and its metabolites and lipid metabolism that has emerged in recent years, aiming to provide a basis for future natural product interventions in NAFLD.
非酒精性脂肪性肝病(NAFLD)是一种以营养过剩和胰岛素抵抗(IR)为主要病因的慢性进行性肝病。肝脏脂质蓄积是导致这一系列变化的核心因素。因此,针对肝脏脂质代谢和炎症反应途径的治疗干预措施在NAFLD治疗方面具有很大的前景。此外,肠道微生物群(GM)与宿主健康之间存在密切联系。GM及其代谢产物可通过多种复杂途径深度参与NAFLD的发生发展,这与多种机制相关。这使得针对单一特定机制的药物难以取得令人满意的治疗效果。在此背景下,天然产物具有干预多个靶点且安全性高的优势。因此,越来越多的研究人员将天然产物视为NAFLD治疗的潜在突破点。值得注意的是,天然产物通过调节GM中有益菌群的丰度来影响肠道黏膜通透性和代谢产物生成,进而调节脂质代谢以减轻肝脏脂肪变性并抑制NAFLD的进展。本文综述了近年来天然产物通过GM及其代谢产物以及脂质代谢干预NAFLD的研究进展,旨在为未来天然产物干预NAFLD提供依据。